1521pintraperitoneal Application of the Trifunctional Monoclonal Antibody Catumaxomab in Outpatients with Malignant Ascites Related to Various Epithelial Tumors.
نویسندگان
چکیده
Aim: Catumaxomab (CATU) is a trifunctional monoclonal antibody approved in the European community for the treatment (Tx) of malignant ascites (MA) related to various carcinomas expressing the epithelial cell adhesion molecule (EpCAM). Recently, the majority of CATU treatments is performed in a hospital. We report on our single-institution experience with an outpatient CATU Tx in patients (pts) with MA due to various EpCAM-positive malignancies.
منابع مشابه
Review of catumaxomab in the treatment of malignant ascites
Malignant ascites is frequently found with various solid tumors, and no established treatment options exist, apart from symptomatic paracentesis. Catumaxomab, a trifunctional bispecific monoclonal antibody, has two binding specificities directed to epithelial cell adhesion molecule (EpCAM) and the T cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells, includin...
متن کاملClinical Medicine Insights: Therapeutics
The trifunctional, bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) is a new therapeutic strategy for epithelial cancer patients with symptomatic malignant ascites. The trifunctionality has the advantage of binding tumor cells and simultaneously two different immune effector cells (e.g. macrophages and T-lymphocytes). The unique binding specifities of catumaxomab induce an effective dest...
متن کاملEffective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
PURPOSE Malignant ascites in ovarian carcinoma patients is associated with poor prognosis and reduced quality of life. The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) enhances the antitumor activity by redirecting T cells and Fcgamma receptor I/III--positive accessory cells to the tumor. This multicenter phase I/II dose-escalating study investigated tolerability and efficacy of i...
متن کاملThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers. In this phase II/III trial (EudraCT 2004-000723-15; NCT00836654), cancer pa...
متن کاملNovel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)
THE TRIFUNCTIONAL ANTIBODY (TRAB) CATUMAXOMAB IS CHARACTERIZED BY A UNIQUE ABILITY TO BIND THREE DIFFERENT CELL TYPES: tumor cells; T-cells; and accessory cells. It binds to epithelial cell adhesion molecule (EpCAM) on tumor cells, the CD3 antigen on T-cells, and to type I, IIa, and III Fcγ receptors (FcγRs) on accessory cells (e.g. natural killer cells, dendritic cells, and macrophages). Catum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014